COVID 19 Compulsary Licensing.pptx
•Download as PPTX, PDF•
0 likes•1 view
New Coronavirus 2019 variants are emerging at an increasing rate, causing people to fear another lockdown due to high infection rates. In previous years, international rules have waived IP registrations such as patents in response to emergency situations such as a pandemic (Nature, 2022). Such restrictions would have an impact on vaccine production by having to reveal how the vaccine works, which would otherwise incentivize companies if they had a patent for their invention.
Report
Share
Report
Share
Recommended
Awareness, Perception and Willingness to Receive Covid-19 Vaccines by Medical...
This document discusses a study on awareness, perception and willingness to receive COVID-19 vaccines among medical trainees in Nigeria. It provides background on COVID-19 and discusses literature reviewing factors influencing vaccine acceptance among healthcare workers, finding varying levels of willingness globally. The rationale is that understanding trainees' perceptions is important as they influence patients and society, and data is limited in Nigeria. The study aims to investigate perception and willingness among trainees in Southwest Nigeria to identify perceptions and fears to address myths.
Differences among Pandemics Vaccines and Traditional Vaccines - Group 4
Bioprocess Technology assignment
Group 4: Nofia Fira Sagrang, Yvonne Lie Sylvia Oh Wen Shuen, Sonny Roy
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
The document discusses the manufacturing process for COVID-19 vaccines. It describes the traditional vaccine development process which uses weakened pathogens versus the novel mRNA vaccine process used for COVID-19 vaccines which uses genetic code to produce antigens. The manufacturing process for vaccines involves fermentation, purification, formulation, filling and packaging. Challenges in developing COVID-19 vaccines include limited worldwide distribution due to cold chain requirements, lack of long term safety and efficacy data for novel mRNA vaccines, and ensuring proper vaccine administration to stimulate immunity.
FOGSI POSITION STATEMENT COVID VACCINATION FOR PREGNANT & BREASTFEEDING WOMEN
This document discusses recommendations and guidelines regarding COVID-19 vaccination for pregnant and breastfeeding women. It provides information on the current COVID-19 situation globally and in India, the different types of COVID vaccines available in India, benefits of vaccination for the general population and pregnant women, safety of the vaccines for pregnant women, and international recommendations that vaccination should be offered to pregnant women similar to non-pregnant individuals based on risk-benefit analysis. The document concludes by stating current recommendations in India do not support vaccination of pregnant or breastfeeding women due to lack of safety data, but international organizations support vaccination for pregnant women.
Progress on COVID-19 Vaccine Development
The document discusses progress on COVID-19 vaccine development. It outlines the typical vaccine development process, including exploratory, pre-clinical, clinical trial, and regulatory approval stages. For COVID-19 vaccines, 28 candidates are currently in clinical trials, with 6 in Phase III. Two vaccines have received limited or early approval - one by China and one by Russia, though the WHO has not yet approved any vaccine. It may still take 12-18 months to develop an approved vaccine. Continued preventative measures are still needed while vaccine development progresses.
Corona vaccine update
1. The document discusses various questions and answers regarding the Corona virus vaccine. It provides information on the different types of vaccines including whole virus, protein subunit, nucleic acid and viral vector vaccines.
2. Details are given about Indian vaccines like Covaxin and Covishield, developed by Bharat Biotech and Serum Institute of India respectively.
3. Practical issues regarding registration and administration of the vaccine through the CoWIN portal are outlined in steps. Precautions to be taken by cancer patients in taking the vaccine are also explained.
CEPI's 100 DAYS AMBITION - HOW DO WE DEVELOP A VACCINE IN 100 DAYS
CEPI's 100 Days Mission aims to develop a vaccine within 100 days from when a pathogen is sequenced or the need for a vaccine is recognized to initial availability. This would have allowed for vaccines to be available months earlier in the COVID-19 pandemic. CEPI is pursuing several strategies to achieve this goal, including developing prototype vaccine libraries for multiple virus families, building more distributed global manufacturing capacity, and rethinking clinical trial and regulatory approaches to allow for more real-world evidence collection in emergencies. The goal is extremely ambitious but CEPI believes that with vision and collaboration, significant improvements in response time are possible.
LEVERAGING PRIVATE-PUBLIC PARTNERSHIPS IN COVID-19 PANDEMIC RESPONSE
The document discusses leveraging private-public partnerships (PPPs) in COVID-19 pandemic response. It provides context on global vaccine trends pre-COVID, then discusses the major impacts of the pandemic on clinical development, trials, and manufacturing. It highlights the roles of developing country vaccine manufacturers and IVI in responding through PPPs. IVI in particular has built partnerships across regions and leveraged over $30 million to develop affordable vaccines for cholera, typhoid and other diseases.
Recommended
Awareness, Perception and Willingness to Receive Covid-19 Vaccines by Medical...
This document discusses a study on awareness, perception and willingness to receive COVID-19 vaccines among medical trainees in Nigeria. It provides background on COVID-19 and discusses literature reviewing factors influencing vaccine acceptance among healthcare workers, finding varying levels of willingness globally. The rationale is that understanding trainees' perceptions is important as they influence patients and society, and data is limited in Nigeria. The study aims to investigate perception and willingness among trainees in Southwest Nigeria to identify perceptions and fears to address myths.
Differences among Pandemics Vaccines and Traditional Vaccines - Group 4
Bioprocess Technology assignment
Group 4: Nofia Fira Sagrang, Yvonne Lie Sylvia Oh Wen Shuen, Sonny Roy
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
The document discusses the manufacturing process for COVID-19 vaccines. It describes the traditional vaccine development process which uses weakened pathogens versus the novel mRNA vaccine process used for COVID-19 vaccines which uses genetic code to produce antigens. The manufacturing process for vaccines involves fermentation, purification, formulation, filling and packaging. Challenges in developing COVID-19 vaccines include limited worldwide distribution due to cold chain requirements, lack of long term safety and efficacy data for novel mRNA vaccines, and ensuring proper vaccine administration to stimulate immunity.
FOGSI POSITION STATEMENT COVID VACCINATION FOR PREGNANT & BREASTFEEDING WOMEN
This document discusses recommendations and guidelines regarding COVID-19 vaccination for pregnant and breastfeeding women. It provides information on the current COVID-19 situation globally and in India, the different types of COVID vaccines available in India, benefits of vaccination for the general population and pregnant women, safety of the vaccines for pregnant women, and international recommendations that vaccination should be offered to pregnant women similar to non-pregnant individuals based on risk-benefit analysis. The document concludes by stating current recommendations in India do not support vaccination of pregnant or breastfeeding women due to lack of safety data, but international organizations support vaccination for pregnant women.
Progress on COVID-19 Vaccine Development
The document discusses progress on COVID-19 vaccine development. It outlines the typical vaccine development process, including exploratory, pre-clinical, clinical trial, and regulatory approval stages. For COVID-19 vaccines, 28 candidates are currently in clinical trials, with 6 in Phase III. Two vaccines have received limited or early approval - one by China and one by Russia, though the WHO has not yet approved any vaccine. It may still take 12-18 months to develop an approved vaccine. Continued preventative measures are still needed while vaccine development progresses.
Corona vaccine update
1. The document discusses various questions and answers regarding the Corona virus vaccine. It provides information on the different types of vaccines including whole virus, protein subunit, nucleic acid and viral vector vaccines.
2. Details are given about Indian vaccines like Covaxin and Covishield, developed by Bharat Biotech and Serum Institute of India respectively.
3. Practical issues regarding registration and administration of the vaccine through the CoWIN portal are outlined in steps. Precautions to be taken by cancer patients in taking the vaccine are also explained.
CEPI's 100 DAYS AMBITION - HOW DO WE DEVELOP A VACCINE IN 100 DAYS
CEPI's 100 Days Mission aims to develop a vaccine within 100 days from when a pathogen is sequenced or the need for a vaccine is recognized to initial availability. This would have allowed for vaccines to be available months earlier in the COVID-19 pandemic. CEPI is pursuing several strategies to achieve this goal, including developing prototype vaccine libraries for multiple virus families, building more distributed global manufacturing capacity, and rethinking clinical trial and regulatory approaches to allow for more real-world evidence collection in emergencies. The goal is extremely ambitious but CEPI believes that with vision and collaboration, significant improvements in response time are possible.
LEVERAGING PRIVATE-PUBLIC PARTNERSHIPS IN COVID-19 PANDEMIC RESPONSE
The document discusses leveraging private-public partnerships (PPPs) in COVID-19 pandemic response. It provides context on global vaccine trends pre-COVID, then discusses the major impacts of the pandemic on clinical development, trials, and manufacturing. It highlights the roles of developing country vaccine manufacturers and IVI in responding through PPPs. IVI in particular has built partnerships across regions and leveraged over $30 million to develop affordable vaccines for cholera, typhoid and other diseases.
Seminar5
The document discusses the current status, pathophysiology, and principles of COVID-19 management and implications for physiotherapy. It provides details on the origin and spread of COVID-19, the virus's structure and mechanism of entering host cells, and the impact on multiple organ systems. Recommendations are made for personal protective equipment when performing respiratory physiotherapy techniques that produce aerosols, such as airway clearance and coughing exercises. Developing vaccines and treatments are important areas of research given the lack of existing prophylactics or therapeutics for COVID-19.
Natural Approach Targeting Gut Dysbiosis - Hipersensitivity - Inflammation Tr...
This document discusses natural approaches for targeting the gut dysbiosis-hypersensitivity-inflammation triad in COVID-19. It covers the gut microbiome and its role in health. Probiotics, prebiotics, symbiotics, healthy diet and herbs are proposed as opportunities to impact the triad and focus on gut health as preventive approaches for COVID-19. Clinical trials studying the gut microbiota in COVID-19 patients are also discussed. The document examines lessons from China on herbal medicine and TCM influence on the gut microbiota. Current work in Indonesia on formulating symbiotic supplements combining probiotics and indigenous herbs is mentioned.
HIV VACCINES; DEVELOPMENT AND CHALLENGES.pptx
This document discusses the development and challenges of HIV vaccines. Over 250 clinical trials have been conducted since the 1980s but an effective vaccine remains elusive due to biological challenges like HIV's ability to mutate. Newer vaccine approaches like mRNA vaccines show promise, with Moderna announcing positive results from a Phase 1 trial of their mRNA HIV vaccine. However, developing a vaccine that provides broad, long-lasting protection against diverse HIV strains and subtypes continues to be hampered by regulatory hurdles and a lack of funding that matches the burden of HIV in developing countries.
HealthBIO 2020_Tim Schenk_Janssen Finland
Presentation at HealthBIO 2020: How COVID-19 is Changing the Approach for the Vaccine Development Process
India Contribute to world.pptx
COVID-19 is a respiratory illness caused by a novel coronavirus (SARS-CoV-2) that emerged in Wuhan, China in late 2019. Symptoms include fever, dry cough, and shortness of breath. The incubation period is up to 14 days. The virus spread rapidly globally within 3 months, infecting over 29 million people worldwide by April 2020. On March 11, 2020, the WHO declared COVID-19 a pandemic due to its worldwide spread and severe health impacts, especially on the elderly and those with preexisting conditions. The pandemic has caused major economic impacts including a projected 4% contraction of global GDP in 2020 and the loss of 225 million full-time jobs.
Corona virus
The 2019–20 coronavirus pandemic is an ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[4] The outbreak was first identified in Wuhan, Hubei, China, in December 2019, and was recognized as a pandemic by the World Health Organization (WHO) on 11 March 2020.[5] As of 25 March, more than 422,000 cases of COVID-19 have been reported in more than 190 countries and territories, resulting in more than 18,900 deaths and more than 109,000 recoveries.
All about Covid-19 Vaccine Development
Disclaimer -
The Content belongs to WHO (World Health Organisation). Sharing here is just to spread awareness about Covid-19.
https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update37-vaccine-development.pdf?sfvrsn=2581e994_6
Prospects and Problems of Development of Candidate Vaccine against COVID 19
There is an urgent need to develop a vaccine against coronavirus disease 2019 COVID 19 , which is caused by a new coronavirus, severe acute respiratory syndrome coronavirus type 2 SARS CoV 2 infection. Although vaccine development typically requires 3 to 5 years, there is a possibility that the vaccine developed for either severe acute respiratory syndrome SARS or the middle east respiratory syndrome MERS could be used against COVID 19 as well. Therefore, a vaccine against COVID 19 is expected to be commercialized within 1 to 2 years. If so, it will be the fastest vaccine development in human history.In this review, we have summarized the information released as of April 10, 2020. Takuma Hayashi | Yasuaki Amano | Takashi Ura | Ikuo Konishi "Prospects and Problems of Development of Candidate Vaccine against COVID-19" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-2 , February 2021, URL: https://www.ijtsrd.com/papers/ijtsrd38521.pdf Paper Url: https://www.ijtsrd.com/medicine/other/38521/prospects-and-problems-of-development-of-candidate-vaccine-against-covid19/takuma-hayashi
Covid 19 vaccines ,ramesh c k
COVID-19 VACCINES Myths Vs Facts
Vaccines types
How they work ?
Recombinant vaccines
Why Covid Vaccines?
Covid Vaccines
Vaccine Usage in the world
In the discussion
Facts vs Myths-
Some Tips for Vaccination
Mahoney 3rd Wvc Dengue Regulation V2
1) Development of dengue vaccines requires addressing regulatory issues like evaluating efficacy against the four virus serotypes and safety regarding antibody-dependent enhancement.
2) Clinical trials are most likely to occur first in developing countries with dengue, where discussions among regulators can define the approval pathway with WHO's guidance.
3) It is important to standardize diagnostic tests and identify a correlate of protection to help evaluate vaccines.
Vaccine security meeting - development amnd perspectives - D.John
Vaccine security Meeting
Rome Italy FAO HQ
23-24 January 2020
Pillar I - Improve\1.3 Emerg Vacc\Vaccine Security Meeting\PPTs final
VaccinateWConfidence-Immunization-Coordinators_508 (2).pptx
This document provides guidance for building confidence in COVID-19 vaccines among healthcare personnel and patients. It discusses the COVID-19 vaccines that are expected to receive emergency authorization, how they were tested and monitored for safety, and strategies for mitigating side effects like fever and soreness that may cause absenteeism. It also outlines elements of vaccine confidence like safety, effectiveness, and ease of access. Recommended strategies to increase confidence include engaging leaders to promote vaccines, addressing common concerns, and emphasizing the role of healthcare workers in ending the pandemic.
Consensus Recommendations on Immunization & IAP Immunization Timetable 2012
The document provides recommendations from a committee on immunization on rotavirus, Hib, and pneumococcal conjugate vaccines. Some key points:
1) The committee reviewed data on the burden of rotavirus disease in India and efficacy of current rotavirus vaccines. However, data gaps remain regarding disease epidemiology and optimal use of vaccines in India.
2) For rotavirus vaccines, the committee stresses the need for more Indian data and optimizing the administration schedule to improve protective efficacy. Safety data on intussusception following vaccination in India is limited.
3) Regarding Hib and pneumococcal vaccines, the committee calls for more Indian studies on disease prevalence and impact to help guide vaccine recommendations and policy
Mechanism of different types of vaccines in development
This document discusses five main types of vaccine technologies: live-attenuated vaccines, inactivated vaccines, subunit vaccines, viral vector vaccines, and messenger RNA (mRNA) vaccines. For each technology, it provides examples of existing vaccines and candidates in development for COVID-19. Live-attenuated vaccines contain weakened live pathogens, while inactivated vaccines use killed whole pathogens. Subunit vaccines contain fragments of pathogens, and viral vector vaccines use harmless viruses to deliver genetic code for antigens. mRNA vaccines teach the body to produce protein antigens to trigger immunity. The Pfizer and Moderna COVID-19 vaccines are mRNA-based.
Covid vaccination training.pptx
The document provides information about COVID-19 vaccination training slides. It notes that the slides should be selected depending on the immunizer's background and role in delivering the COVID-19 vaccine program. Additional vaccine details are provided at the end for vaccines that receive regulatory approval. The information may change as knowledge about COVID-19 and vaccines continues to develop.
covidvaccines-210821171459...........pptx
The document provides information about COVID-19 vaccines in India. It discusses two main vaccines approved for use - Covishield and Covaxin. Covishield is the local version of the Oxford-AstraZeneca vaccine manufactured by the Serum Institute of India. Covaxin is Bharat Biotech's indigenous vaccine developed in collaboration with ICMR. Both vaccines received emergency use approval from the Drugs Controller General of India. The document also provides details on vaccine efficacy, dosing schedules, manufacturing companies, approval process, vaccination coverage trends in India, and strategies to build confidence in COVID-19 vaccines.
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...
This document discusses developing therapeutic strategies for COVID-19. It outlines three main approaches: targeting the virus's binding to host cells, targeting viral replication inside cells, and repurposing approved drugs. Several drugs are discussed, including remdesivir, chloroquine, hydroxychloroquine, and azithromycin. While no consensus treatment has been found, repurposed drugs have shown promise. Continued research efforts provide hope that an effective treatment can be developed to combat this pandemic.
Ways Forward – Vaccine Manufacturing Tomorrow
In this webinar, you will learn:
Trends in vaccine manufacturing
Innovative solutions in facility design
Case studies and proposals for future vaccine factories
Considerations while setting up Quality Management Systems (QMSs)
How validation helps accelerate regulatory approval
Detailed description:
How we see vaccine manufacturing evolving due to the COVID-19 pandemic, how could it further transform, and what are some solutions we can incorporate to prepare ourselves for next-generation facilities?
The unprecedented COVID-19 pandemic has driven significant tech acceleration around the world, including methods of vaccine manufacturing. Together with the concept of Bioprocessing 4.0, digital biomanufacturing enables centralized orchestration of production process and data management, and a "Facility of the Future" characterized by intensified, continuous, predictive, and autonomous operations. In this presentation, we will explore trends in vaccine manufacturing, including fully single-use processes, closed processing, modular facilities, and platform manufacturing. We will also discuss some key considerations when setting up Quality Management Systems for novel facilities, and how to speed up regulatory approval through best practices in facility validation.
Ways Forward – Vaccine Manufacturing Tomorrow
In this webinar, you will learn:
Trends in vaccine manufacturing
Innovative solutions in facility design
Case studies and proposals for future vaccine factories
Considerations while setting up Quality Management Systems (QMSs)
How validation helps accelerate regulatory approval
Detailed description:
How we see vaccine manufacturing evolving due to the COVID-19 pandemic, how could it further transform, and what are some solutions we can incorporate to prepare ourselves for next-generation facilities?
The unprecedented COVID-19 pandemic has driven significant tech acceleration around the world, including methods of vaccine manufacturing. Together with the concept of Bioprocessing 4.0, digital biomanufacturing enables centralized orchestration of production process and data management, and a "Facility of the Future" characterized by intensified, continuous, predictive, and autonomous operations. In this presentation, we will explore trends in vaccine manufacturing, including fully single-use processes, closed processing, modular facilities, and platform manufacturing. We will also discuss some key considerations when setting up Quality Management Systems for novel facilities, and how to speed up regulatory approval through best practices in facility validation.
Document
The document discusses the key characteristics of an ideal COVID-19 vaccine. It outlines 9 important landscapes that should be considered when designing such a vaccine: 1) Safety, 2) Efficacy, 3) Use of adjuvants or delivery systems, 4) Purity and sterility, 5) Ability to protect against multiple strains or genotypes (valency), 6) Thermal stability, 7) Route of administration, preferably mucosal, 8) Affordability, and 9) Acceptability to the public and health systems. The vaccine should maximize protection while minimizing risks to recipients.
Histololgy of Female Reproductive System.pptx
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
The Best Ayurvedic Antacid Tablets in India
Treat the symptoms of indigestion, heartburn and stomach reflux with the 10 Best Ayurvedic Antacid Tablets in India.
More Related Content
Similar to COVID 19 Compulsary Licensing.pptx
Seminar5
The document discusses the current status, pathophysiology, and principles of COVID-19 management and implications for physiotherapy. It provides details on the origin and spread of COVID-19, the virus's structure and mechanism of entering host cells, and the impact on multiple organ systems. Recommendations are made for personal protective equipment when performing respiratory physiotherapy techniques that produce aerosols, such as airway clearance and coughing exercises. Developing vaccines and treatments are important areas of research given the lack of existing prophylactics or therapeutics for COVID-19.
Natural Approach Targeting Gut Dysbiosis - Hipersensitivity - Inflammation Tr...
This document discusses natural approaches for targeting the gut dysbiosis-hypersensitivity-inflammation triad in COVID-19. It covers the gut microbiome and its role in health. Probiotics, prebiotics, symbiotics, healthy diet and herbs are proposed as opportunities to impact the triad and focus on gut health as preventive approaches for COVID-19. Clinical trials studying the gut microbiota in COVID-19 patients are also discussed. The document examines lessons from China on herbal medicine and TCM influence on the gut microbiota. Current work in Indonesia on formulating symbiotic supplements combining probiotics and indigenous herbs is mentioned.
HIV VACCINES; DEVELOPMENT AND CHALLENGES.pptx
This document discusses the development and challenges of HIV vaccines. Over 250 clinical trials have been conducted since the 1980s but an effective vaccine remains elusive due to biological challenges like HIV's ability to mutate. Newer vaccine approaches like mRNA vaccines show promise, with Moderna announcing positive results from a Phase 1 trial of their mRNA HIV vaccine. However, developing a vaccine that provides broad, long-lasting protection against diverse HIV strains and subtypes continues to be hampered by regulatory hurdles and a lack of funding that matches the burden of HIV in developing countries.
HealthBIO 2020_Tim Schenk_Janssen Finland
Presentation at HealthBIO 2020: How COVID-19 is Changing the Approach for the Vaccine Development Process
India Contribute to world.pptx
COVID-19 is a respiratory illness caused by a novel coronavirus (SARS-CoV-2) that emerged in Wuhan, China in late 2019. Symptoms include fever, dry cough, and shortness of breath. The incubation period is up to 14 days. The virus spread rapidly globally within 3 months, infecting over 29 million people worldwide by April 2020. On March 11, 2020, the WHO declared COVID-19 a pandemic due to its worldwide spread and severe health impacts, especially on the elderly and those with preexisting conditions. The pandemic has caused major economic impacts including a projected 4% contraction of global GDP in 2020 and the loss of 225 million full-time jobs.
Corona virus
The 2019–20 coronavirus pandemic is an ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[4] The outbreak was first identified in Wuhan, Hubei, China, in December 2019, and was recognized as a pandemic by the World Health Organization (WHO) on 11 March 2020.[5] As of 25 March, more than 422,000 cases of COVID-19 have been reported in more than 190 countries and territories, resulting in more than 18,900 deaths and more than 109,000 recoveries.
All about Covid-19 Vaccine Development
Disclaimer -
The Content belongs to WHO (World Health Organisation). Sharing here is just to spread awareness about Covid-19.
https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update37-vaccine-development.pdf?sfvrsn=2581e994_6
Prospects and Problems of Development of Candidate Vaccine against COVID 19
There is an urgent need to develop a vaccine against coronavirus disease 2019 COVID 19 , which is caused by a new coronavirus, severe acute respiratory syndrome coronavirus type 2 SARS CoV 2 infection. Although vaccine development typically requires 3 to 5 years, there is a possibility that the vaccine developed for either severe acute respiratory syndrome SARS or the middle east respiratory syndrome MERS could be used against COVID 19 as well. Therefore, a vaccine against COVID 19 is expected to be commercialized within 1 to 2 years. If so, it will be the fastest vaccine development in human history.In this review, we have summarized the information released as of April 10, 2020. Takuma Hayashi | Yasuaki Amano | Takashi Ura | Ikuo Konishi "Prospects and Problems of Development of Candidate Vaccine against COVID-19" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-2 , February 2021, URL: https://www.ijtsrd.com/papers/ijtsrd38521.pdf Paper Url: https://www.ijtsrd.com/medicine/other/38521/prospects-and-problems-of-development-of-candidate-vaccine-against-covid19/takuma-hayashi
Covid 19 vaccines ,ramesh c k
COVID-19 VACCINES Myths Vs Facts
Vaccines types
How they work ?
Recombinant vaccines
Why Covid Vaccines?
Covid Vaccines
Vaccine Usage in the world
In the discussion
Facts vs Myths-
Some Tips for Vaccination
Mahoney 3rd Wvc Dengue Regulation V2
1) Development of dengue vaccines requires addressing regulatory issues like evaluating efficacy against the four virus serotypes and safety regarding antibody-dependent enhancement.
2) Clinical trials are most likely to occur first in developing countries with dengue, where discussions among regulators can define the approval pathway with WHO's guidance.
3) It is important to standardize diagnostic tests and identify a correlate of protection to help evaluate vaccines.
Vaccine security meeting - development amnd perspectives - D.John
Vaccine security Meeting
Rome Italy FAO HQ
23-24 January 2020
Pillar I - Improve\1.3 Emerg Vacc\Vaccine Security Meeting\PPTs final
VaccinateWConfidence-Immunization-Coordinators_508 (2).pptx
This document provides guidance for building confidence in COVID-19 vaccines among healthcare personnel and patients. It discusses the COVID-19 vaccines that are expected to receive emergency authorization, how they were tested and monitored for safety, and strategies for mitigating side effects like fever and soreness that may cause absenteeism. It also outlines elements of vaccine confidence like safety, effectiveness, and ease of access. Recommended strategies to increase confidence include engaging leaders to promote vaccines, addressing common concerns, and emphasizing the role of healthcare workers in ending the pandemic.
Consensus Recommendations on Immunization & IAP Immunization Timetable 2012
The document provides recommendations from a committee on immunization on rotavirus, Hib, and pneumococcal conjugate vaccines. Some key points:
1) The committee reviewed data on the burden of rotavirus disease in India and efficacy of current rotavirus vaccines. However, data gaps remain regarding disease epidemiology and optimal use of vaccines in India.
2) For rotavirus vaccines, the committee stresses the need for more Indian data and optimizing the administration schedule to improve protective efficacy. Safety data on intussusception following vaccination in India is limited.
3) Regarding Hib and pneumococcal vaccines, the committee calls for more Indian studies on disease prevalence and impact to help guide vaccine recommendations and policy
Mechanism of different types of vaccines in development
This document discusses five main types of vaccine technologies: live-attenuated vaccines, inactivated vaccines, subunit vaccines, viral vector vaccines, and messenger RNA (mRNA) vaccines. For each technology, it provides examples of existing vaccines and candidates in development for COVID-19. Live-attenuated vaccines contain weakened live pathogens, while inactivated vaccines use killed whole pathogens. Subunit vaccines contain fragments of pathogens, and viral vector vaccines use harmless viruses to deliver genetic code for antigens. mRNA vaccines teach the body to produce protein antigens to trigger immunity. The Pfizer and Moderna COVID-19 vaccines are mRNA-based.
Covid vaccination training.pptx
The document provides information about COVID-19 vaccination training slides. It notes that the slides should be selected depending on the immunizer's background and role in delivering the COVID-19 vaccine program. Additional vaccine details are provided at the end for vaccines that receive regulatory approval. The information may change as knowledge about COVID-19 and vaccines continues to develop.
covidvaccines-210821171459...........pptx
The document provides information about COVID-19 vaccines in India. It discusses two main vaccines approved for use - Covishield and Covaxin. Covishield is the local version of the Oxford-AstraZeneca vaccine manufactured by the Serum Institute of India. Covaxin is Bharat Biotech's indigenous vaccine developed in collaboration with ICMR. Both vaccines received emergency use approval from the Drugs Controller General of India. The document also provides details on vaccine efficacy, dosing schedules, manufacturing companies, approval process, vaccination coverage trends in India, and strategies to build confidence in COVID-19 vaccines.
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...
This document discusses developing therapeutic strategies for COVID-19. It outlines three main approaches: targeting the virus's binding to host cells, targeting viral replication inside cells, and repurposing approved drugs. Several drugs are discussed, including remdesivir, chloroquine, hydroxychloroquine, and azithromycin. While no consensus treatment has been found, repurposed drugs have shown promise. Continued research efforts provide hope that an effective treatment can be developed to combat this pandemic.
Ways Forward – Vaccine Manufacturing Tomorrow
In this webinar, you will learn:
Trends in vaccine manufacturing
Innovative solutions in facility design
Case studies and proposals for future vaccine factories
Considerations while setting up Quality Management Systems (QMSs)
How validation helps accelerate regulatory approval
Detailed description:
How we see vaccine manufacturing evolving due to the COVID-19 pandemic, how could it further transform, and what are some solutions we can incorporate to prepare ourselves for next-generation facilities?
The unprecedented COVID-19 pandemic has driven significant tech acceleration around the world, including methods of vaccine manufacturing. Together with the concept of Bioprocessing 4.0, digital biomanufacturing enables centralized orchestration of production process and data management, and a "Facility of the Future" characterized by intensified, continuous, predictive, and autonomous operations. In this presentation, we will explore trends in vaccine manufacturing, including fully single-use processes, closed processing, modular facilities, and platform manufacturing. We will also discuss some key considerations when setting up Quality Management Systems for novel facilities, and how to speed up regulatory approval through best practices in facility validation.
Ways Forward – Vaccine Manufacturing Tomorrow
In this webinar, you will learn:
Trends in vaccine manufacturing
Innovative solutions in facility design
Case studies and proposals for future vaccine factories
Considerations while setting up Quality Management Systems (QMSs)
How validation helps accelerate regulatory approval
Detailed description:
How we see vaccine manufacturing evolving due to the COVID-19 pandemic, how could it further transform, and what are some solutions we can incorporate to prepare ourselves for next-generation facilities?
The unprecedented COVID-19 pandemic has driven significant tech acceleration around the world, including methods of vaccine manufacturing. Together with the concept of Bioprocessing 4.0, digital biomanufacturing enables centralized orchestration of production process and data management, and a "Facility of the Future" characterized by intensified, continuous, predictive, and autonomous operations. In this presentation, we will explore trends in vaccine manufacturing, including fully single-use processes, closed processing, modular facilities, and platform manufacturing. We will also discuss some key considerations when setting up Quality Management Systems for novel facilities, and how to speed up regulatory approval through best practices in facility validation.
Document
The document discusses the key characteristics of an ideal COVID-19 vaccine. It outlines 9 important landscapes that should be considered when designing such a vaccine: 1) Safety, 2) Efficacy, 3) Use of adjuvants or delivery systems, 4) Purity and sterility, 5) Ability to protect against multiple strains or genotypes (valency), 6) Thermal stability, 7) Route of administration, preferably mucosal, 8) Affordability, and 9) Acceptability to the public and health systems. The vaccine should maximize protection while minimizing risks to recipients.
Similar to COVID 19 Compulsary Licensing.pptx (20)
Natural Approach Targeting Gut Dysbiosis - Hipersensitivity - Inflammation Tr...
Natural Approach Targeting Gut Dysbiosis - Hipersensitivity - Inflammation Tr...
Prospects and Problems of Development of Candidate Vaccine against COVID 19
Prospects and Problems of Development of Candidate Vaccine against COVID 19
Vaccine security meeting - development amnd perspectives - D.John
Vaccine security meeting - development amnd perspectives - D.John
VaccinateWConfidence-Immunization-Coordinators_508 (2).pptx
VaccinateWConfidence-Immunization-Coordinators_508 (2).pptx
Consensus Recommendations on Immunization & IAP Immunization Timetable 2012
Consensus Recommendations on Immunization & IAP Immunization Timetable 2012
Mechanism of different types of vaccines in development
Mechanism of different types of vaccines in development
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...
Recently uploaded
Histololgy of Female Reproductive System.pptx
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
The Best Ayurvedic Antacid Tablets in India
Treat the symptoms of indigestion, heartburn and stomach reflux with the 10 Best Ayurvedic Antacid Tablets in India.
Top 10 Best Ayurvedic Kidney Stone Syrups in India
we have mentioned the best 10 ayurvedic Kidney Stone Syrups. You can check all these products and choose the best one for yourself.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest VersionKetone bodies and metabolism-biochemistry
This slide consists of all the topics of ketone . This can be used for exam purpose for writing about Diabetic keto acidosis etc . Thank you
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...rightmanforbloodline
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.A Classical Text Review on Basavarajeeyam
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Do you have abnormal smell after periods? It may be vaginitis. Do not worry, herbal medicine Fuyan Pill can help you get a cure.
Journal Article Review on Rasamanikya
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
The Electrocardiogram - Physiologic Principles
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Recently uploaded (20)
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
COVID 19 Compulsary Licensing.pptx
- 1. Problem
- 2. • New Coronavirus 2019 variants are emerging at an increasing rate, causing people to fear another lockdown due to high infection rates. In previous years, international rules have waived IP registrations such as patents in response to emergency situations such as a pandemic (Nature, 2022). Such restrictions would have an impact on vaccine production by having to reveal how the vaccine works, which would otherwise incentivize companies if they had a patent for their invention. • There are numerous approaches to developing a vaccine, including using a whole-microbe of virus that is inactivated or attenuated and can be injected into the body, vaccine methods that use the infectious part of the microbe, and others that use genetic materials in the virus that can be injected into the body (WHO, 2021). Most of these vaccine development methods necessitate a lengthy development period and clinical trials, which are inappropriate in high infection rate scenarios.
- 3. • Suggestive Solution: • Nanoparticles can be used to encapsulate virus genetic information. If the lipid-nanoparticles are injected into the body, the encapsulated genetic materials can be released, eventually forming antibodies. This method can be used to accelerate the COVID vaccine's development and clinical trials.
- 4. • Nature Publishing Group. (2022, March 29). Time is running out for COVID vaccine patent waivers. Nature News. Retrieved from https://www.nature.com/articles/d41586-022-00878-x • World Health Organization. (2021). The different types of covid-19 vaccines. World Health Organization. Retrieved from https://www.who.int/news-room/feature-stories/detail/the-race-for- a-covid-19-vaccine-explained